| 198 | 0 | 173 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 对高血压合并卒中二级预防降压药物方案的选择进行网状Meta分析。方法 检索中国知网、维普、万方数据库、CochraneLibrary、PubMed、Embase数据库有关高血压合并卒中二级预防降压药物治疗的随机对照试验（RCTs）。采用Cochrane偏倚风险评估工具5.2评价文献质量和偏倚风险，采用Stata 15.0和RevMan 5.2软件进行网状Meta分析。评价指标为卒中复发率（SRR）或卒中死亡率（SMR）。效应量采用优势比（OR）以及95%置信区间（95%CI）、累积概率排序曲线面积（SUCRA）评价。结果 最终纳入文献38篇，共涉及患者44 091例，涉及治疗方案13种：安慰剂或常规治疗（Placebo）、血管紧张素转化酶抑制剂（ACEI）、钙通道阻滞剂（CCB）、利尿剂（Diu）、血管紧张素Ⅱ受体拮抗剂（ARB）、β受体阻滞剂（BB）、CCB+Diu、Diu+中枢性降压药（CNS）、ACEI+CCB、ACEI+叶酸（FA）、ARB+Diu、ACEI+Diu、ACEI+BB。所有文献均未描述结果完整性、选择性报告和其他偏倚等。网状Meta分析结果提示，在降低高血压合并卒中患者SRR方面，ARB优于Placebo、Diu、CCB,ACEI+Diu优于ACEI、Diu+CNS,ACEI+CCB优于CCB、ACEI、Diu+CNS；在降低SMR方面，ARB、ACEI优于CCB,ARB、ACEI+CCB优于BB。二级预防降压药物在降低高血压合并卒中患者SRR方面的SUCRA排序为ACEI+CCB> ARB> ACEI+Diu>CCB+Diu>BB>Placebo> ACEI+FA> ACEI+BB> ARB+Diu> Diu> CCB> ACEI> Diu+CNS；在降低高血压合并卒中患者SMR方面的SUCRA排序为ARB> ACEI+CCB> Diu+CNS> ACEI+BB> Placebo> CCB> ACEI> BB。结论 高血压合并卒中二级预防降压药物方案选择推荐ACEI+CCB和ARB，但还需要多中心、大样本和高质量RCT，对该结论进行验证。
Abstract：AIM To explore the efficacy of antihypertensive agents for secondary prevention of hypertension complicated with ischemic stroke. METHODS A literature search was conducted for randomized controlled trials(RCTs) regarding antihypertensive agents for secondary prevention of hypertension complicated with ischemic stroke from databases involving China National Knowledge Infrastructure(CNKI), VIP database, WanFang database, Cochrane Library, PubMed and Embase databases from their inception to 2023. The quality and risk of bias of the literature were assessed by the Cochrane Collaboration's tool(version 5.2). The evaluation indicators were stroke recurrence rate(SRR) or stroke mortality rate(SMR). The effect size was measured using odds ratios(OR) with a 95% confidence interval(95%CI)and the surface under the cumulative ranking curve(SUCRA) for evaluation. RESULTS A total of 38 RCTs included 44091 patients, involving 13 kinds of therapy such as placebo or basic treatment, angiotensin-converting enzyme inhibitor(ACEI), calcium channel blocker(CCB), diuretic(Diu), angiotensin Ⅱ receptor antagonist(ARB), β-receptor blocker(BB),CCB+Diu, Diu+central nervous system hypotension(CNS), ACEI+CCB, ACEI+folic acid(FA), ARB+Diu, ACEI+Diu, and ACEI+BB. None of the literature described the completeness of the results, selective reporting, or other biases. Network Meta-analysis 95%CI showed, as for SRR, ARB was superior to Placebo, Diu, and CCB, ACEI+Diu was superior to ACEI,Diu+CNS, and ACEI+CCB was superior to CCB, ACEI, Diu+CNS. In reducing SMR, ARB and ACEI were superior to CCB, and ARB and ACEI+CCB were superior to BB. In term of reducing SRR, the SUCRA order of antihypertensive agents for secondary prevention of hypertension complicated with ischemic stroke was as follows: ACEI+CCB > ARB > ACEI+Diu > CCB+Diu > BB > Placebo > ACEI+FA > ACEI+BB > ARB+Diu > Diu > CCB > ACEI > Diu+CNS. In reducing SMR, the SUCRA order was: ARB > ACEI+CCB > Diu+CNS > ACEI+BB > Placebo > CCB > ACEI > BB.CONCLUSION Based on the existing clinical evidence, ACEI+CCB and ARB are recommended for the selection of antihypertensive agents for secondary prevention of hypertension complicated with ischemic stroke. However, further multicenter, large-sample, high-quality RCTs are needed to validate these findings.
[1] MILLS KT, STEFANESCU A, HE J. The global epidemiology of hypertension[J]. Nat Rev Nephrol, 2020, 16(4):223.
[2] ZHOU B, PEREL P, MENSAH GA, et al. Global epidemiology,health burden and effective interventions for elevated blood pressure and hypertension[J]. Nat Rev Cardiol, 2021, 18(11):785.
[3]国家心血管病中心.中国心血管健康与疾病报告-2019, 2019[M].北京:科学出版社, 2021.
[4]国家卫生计生委合理用药专家委员会,中国医师协会高血压专业委员会.高血压合理用药指南(第2版)[J].中国医学前沿杂志(电子版), 2017, 9(7):28.
[5]中华医学会,中华医学会临床药学分会,中华医学会杂志社,等.高血压基层合理用药指南[J].中华全科医师杂志, 2021, 20(1):21.
[6]王群,孙世光.交泰丸治疗失眠网络Meta分析[J].中国中西医结合杂志, 2020, 40(5):560.
[7]王群.交泰丸治疗失眠(基础与临床)系统评价与网络Meta分析[D].济南:山东中医药大学, 2017.
[8] CARTER AB. Hypotensive therapy in stroke survivors[J].Lancet, 1970, 1(7645):485.
[9] CARTER A. Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group[J].JAMA, 1974, 229(4):409.
[10] HYPERTENSION-STROKE COOPERATIVE STUDY GROUP.Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group[J]. Stroke, 1993, 24(4):543.
[11] ERIKSSON S, OLOFSSON BO, WESTER PO. Atenolol in secondary prevention after stroke[J]. Cerebrovasc Dis, 1995,5(1):21.
[12] GROUP PC. Post-stroke antihypertensive treatment study. A preliminary result[J]. Chin Med J, 1995, 108(9):710.
[13] WEINBERGER J. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack[J]. Curr Cardiol Rep, 2003,5(2):140.
[14]路方红,魏芳,叶琳,等.培哚普利治疗对防治高血压合并脑卒中患者并发症的临床试验[J].中国循证医学杂志, 2002, 2(3):162.
[15] BOSCH J, YUSUF S, POGUE J, et al. Use of ramipril in preventing stroke:double blind randomised trial[J]. BMJ, 2002,324(7339):699.
[16] DAHL?F B, DEVEREUX RB, KJELDSEN SE, et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol[J]. Lancet, 2002, 359(9311):995.
[17] TRENKWALDER P, ELMFELDT D, HOFMAN A, et al. The Study on COgnition and Prognosis in the Elderly(SCOPE)-major CV events and stroke in subgroups of patients[J]. Blood Press,2005, 14(1):31.
[18]毛朝旭,卢湘鸿,薛定荣.培哚普利对高血压合并心房颤动患者再次脑卒中的干预[J].高血压杂志, 2003, 11(2):698.
[19] SCHRADER J, LüDERS S, KULSCHEWSKI A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention:principal results of a prospective randomized controlled study(MOSES)[J]. Stroke, 2005, 36(6):1218.
[20] LIU LS, ZHANG YQ, LIU GZ, et al. The Felodipine Event Reduction(FEVER)Study:a randomized long-term placebocontrolled trial in Chinese hypertensive patients[J]. J Hypertens,2005, 23(12):2157.
[21]王文,邓卿,王宪衍,等. 6年降压治疗对脑血管病患者脑卒中再发事件的预防效果[J].中华高血压杂志, 2007, 15(4):281.
[22] OGIHARA T, NAKAO K, FUKUI T, et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension:a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan(CASE-J)trial[J].Hypertens Res, 2008, 31(8):1595.
[23] BECKETT NS, PETERS R, FLETCHER A E, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med, 2008, 358(18):1887.
[24]梁友云,王晓玲,刘宏伟,等.龙泽汤控制缺血性脑卒中时高血压的临床研究[J].河北医学, 2010, 16(3):284.
[25] SANDSET EC, BATH PMW, BOYSEN G, et al. The angiotensinreceptor blocker candesartan for treatment of acute stroke(SCAST):a randomised, placebo-controlled, double-blind trial[J]. Lancet,2011, 377(9767):741.
[26]宋元英,杨彦玲.苯磺酸左旋氨氯地平和依那普利对脑卒中患者血压的调控作用对比[J].中国老年学杂志, 2011, 31(20):4039.
[27]张顺开. ARB在伴有高血压合并房颤脑梗死患者中缺血性脑卒中复发二级预防作用研究[J].中国农村卫生事业管理, 2012,32(1):93.
[28]程文文,傅佳,赵焕,等.马来酸依那普利叶酸片用于脑卒中二级预防的临床研究[J].安徽医科大学学报, 2012, 47(6):670.
[29]陈东骊,张曹进,符永恒,等.高血压合并缺血性脑卒中患者血浆ADMA水平变化及厄贝沙坦干预研究[J].实用医学杂志,2013(10):1613.
[30] OH MS, YU KH, HONG KS, et al. Modest blood pressure reduction with valsartan in acute ischemic stroke:a prospective,randomized, open-label, blinded-end-point trial[J]. Int J Stroke,2015, 10(5):745.
[31]严利南,曾广民,王艾,等.氨氯地平与贝那普利对高血压脑卒中二级预防的效果[J].心脏杂志, 2015, 27(1):34.
[32]侯小东.氨氯地平与贝那普利治疗高血压脑卒中的临床疗效及复发率比较[J].中国处方药, 2015, 13(8):63.
[33]刘桂芳.缬沙坦用于中老年高血压性缺血性脑卒中二级预防的临床效果观察[J].临床合理用药杂志, 2016, 9(8):35.
[34]郝金海.氨氯地平与贝那普利对高血压脑卒中二级预防的效果观察[J].中国社区医师, 2016, 32(18):28.
[35]张小炼.氨氯地平与贝那普利在高血压脑卒中二级预防中的应用效果对比[J].临床合理用药杂志, 2016, 9(6):60.
[36]唐丽艳.贝那普利与氨氯地平在高血压病并发脑卒中患者二级预防中疗效分析[J].中国处方药, 2016, 14(8):55.
[37]张宝慧.探析贝那普利联合氨氯地平对高血压脑卒中二级预防的效果[J].中国社区医师, 2016, 32(2):27.
[38]胡媛媛.氨氯地平联合贝那普利应用于高血压脑卒中预防的临床观察[J].继续医学教育, 2016, 30(1):145.
[39]舒俊.马来酸依那普利叶酸片预防H型高血压脑卒中的临床价值[J].世界最新医学信息文摘, 2016, 16(27):24.
[40]周仕涛.马来酸依那普利叶酸片对H型高血压脑卒中的预防作用[J].临床合理用药杂志, 2017, 10(28):80.
[41]叶林繁,张晓丽,欧春明.马来酸依那普利叶酸片在脑卒中二级预防中的效果及对血压的影响[J].卫生职业教育, 2017, 35(7):137.
[42]李开华.氨氯地平与贝那普利对高血压卒中二级预防的疗效心肌梗死率及复发率影响[J].中国保健营养, 2018,(2):90.
[43]刘翠平,侯永革,朱荣彦,等.马来酸左旋氨氯地平治疗脑卒中合并高血压患者疗效观察[J].河北医药, 2018, 40(21):3277.
[44]蔡嵩,郑成,宫海滨,等.依那普利叶酸片治疗伴有高同型半胱氨酸血症原发性高血压卒中患者临床疗效[J].慢性病学杂志,2020, 21(1):24.
[45]王红.倍他乐克结合氯沙坦治疗对高血压并脑梗死患者缺血性脑卒中复发的效果分析[J].医学理论与实践, 2023, 36(5):762.
[46]中国医疗保健国际交流促进会心血管病学分会.高血压合并冠心病患者血压管理中国专家共识[J].中华医学杂志, 2022,102(10):717.
[47]中国老年医学学会,中国老年医学学会高血压分会,中国老年医学学会认知障碍分会,等.老年高血压合并认知障碍诊疗中国专家共识(2021版)[J].中华高血压杂志, 2021, 7(4):311.
[48]赵连友,孙英贤,李玉明,等.高血压合并动脉粥样硬化防治中国专家共识[J].中华高血压杂志, 2020, 28(2):116.
[49]WEI JK, GALAVIZ KI, KOWALSKI AJ, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications:a systematic review and network meta-analysis[J]. JAMA Netw Open, 2020, 3(2):e1921618.
[50] BONCORAGLIO GB, DEL GIOVANE C, TRAMACERE I.Antihypertensive drugs for secondary prevention after ischemic stroke or transient ischemic attack:a systematic review and metaanalysis[J]. Stroke, 2021, 52(6):1974.
[51] ZHONG XL, DONG Y, XU W, et al. Role of blood pressure management in stroke prevention:a systematic review and network meta-analysis of 93 randomized controlled trials[J]. J Stroke,2021, 23(1):1.
[52] KITAGAWA K, YAMAMOTO Y, ARIMA H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke:a randomized clinical trial and meta-analysis[J]. JAMA Neurol, 2019, 76(11):1309.
[53] PARK H, SOHN SI, LEEM GH, et al. Standard versus intensive blood pressure control in acute ischemic stroke patients successfully treated with endovascular thrombectomy:a systemic review and meta-analysis of randomized controlled trials[J]. J Stroke, 2024, 26(1):54.
基本信息:
DOI：10.19577/j.1007-4406.2024.03.003
中图分类号:R969.3
引用信息:
[1]王群,李萍,崔玉萍,等.高血压合并卒中二级预防降压药物方案选择的网状Meta分析[J].中国临床药学杂志,2024,33(03):176-184.DOI:10.19577/j.1007-4406.2024.03.003.
基金信息:
山东省中医药高层次人才培育项目（编号：鲁卫函[2023]143号）; 山东省自然科学基金（编号ZR2019MH063）; 张红星全国名老中医药专家传承工作室建设项目（编号：国中医药办人教函[2022]75号）; 刘向红全国老中医药专家学术经验继承工作项目（编号：国中医药办人教函[2022]76号）; 山东省重点研发计划项目（编号2019GNC21307）; 山东省医药卫生科技发展计划项目（编号2018WS199）
2024-03-25
2024-03-25